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Development of a Chimeric Plasmodium berghei Strain Expressing the
Repeat Region of the P. vivax Circumsporozoite Protein for In Vivo
Evaluation of Vaccine Efficacy
Diego A. Espinosa,a Anjali Yadava,b Evelina Angov,b Paul L. Maurizio,a Christian F. Ockenhouse,b Fidel Zavalaa
Johns Hopkins Malaria Research Institute and Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Johns
Hopkins University, Baltimore, Maryland, USAa; Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USAb
The development of vaccine candidates against Plasmodium vivax—the most geographically widespread human malaria spe-
cies—is challenged by technical difficulties, such as the lack of in vitro culture systems and availability of animal models. Chime-
ric rodent Plasmodium parasites are safe and useful tools for the preclinical evaluation of new vaccine formulations. We report
the successful development and characterization of chimeric Plasmodium berghei parasites bearing the type I repeat region of P.
vivax circumsporozoite protein (CSP). The P. berghei-P. vivax chimeric strain develops normally in mosquitoes and produces
highly infectious sporozoites that produce patent infection in mice that are exposed to the bites of as few as 3 P. berghei-P.
vivax-infected mosquitoes. Using this transgenic parasite, we demonstrate that monoclonal and polyclonal antibodies against P.
vivax CSP strongly inhibit parasite infection and thus support the notion that these antibodies play an important role in protec-
tive immunity. The chimeric parasites we developed represent a robust model for evaluating protective immune responses
against P. vivax vaccines based on CSP.
The global burden of malaria due to Plasmodium vivax is ap-proximately 70 to 390 million cases annually (1), with around
2.5 billion people living at risk of infection (2). Even though Plas-
modium falciparum remains the leading cause of malaria in Africa,
P. vivax malaria is the most geographically widespread of the hu-
man malarias (2, 3). It is extensively distributed throughout the
tropics, in the Middle East, Asia, the western Pacific, and Latin
America (1–4).
P. vivax malaria was long considered a benign and non-life-
threatening disease; however, recent publications report an in-
creasing number of severe, complicated cases due to P. vivax in-
fections (5, 6). Efforts toward the development of antimalaria
vaccines are still mainly focused on P. falciparum, although P.
vivax malaria is “harder to prevent, diagnose, and treat, and both
species are coendemic” (7). While the importance of a vaccine
targeting P. vivax is recognized, the development of P. vivax ma-
laria vaccines is hampered by insufficient funding and technical
difficulties (2, 8, 9). The lack of in vitro culture systems and suit-
able animal models, for example, imposes a significant limitation
on testing novel vaccine candidates (7, 10).
The circumsporozoite protein (CSP) is the most abundant
protein on the surfaces of sporozoites and is responsible for elic-
iting both T-cell and antibody responses. The plasmodial CSP is
one of the best studied antigens and is considered to be a major
malaria vaccine candidate. RTS,S, the most effective malaria vac-
cine candidate to date, is based on P. falciparum CSP, thus under-
scoring CSP’s immunogenic properties. CSP is comprised of an
immunodominant central repeat region, diverse among Plasmo-
dium species, flanked by two conserved domains: region I at the N
terminus of the repeats and a type I thrombospondin repeat (TSR)
motif C terminal to the repeat region. Early studies in animals
have indicated that antibodies against the repeat region neutralize
the infectivity of sporozoites and confer sterile immunity (11, 12).
Importantly, recent studies in humans vaccinated with RTS,S in-
dicated that protection among vaccinees correlates with the titer
of anti-CSP repeat antibodies (13).
Plasmodium berghei parasites bearing the repeat region of P.
falciparum CSP have been developed and characterized by Persson
et al. (14). These parasites, “antigenically P. falciparum but func-
tionally rodent malaria” (14), are a practical tool for evaluating the
efficacy of human preerythrocytic P. falciparum CSP-based vac-
cine candidates. On the basis of the study by Persson et al., we
developed and characterized a chimeric P. berghei parasite strain
expressing the repeat region of P. vivax (VK210) CSP as a first step
in evaluating vaccine candidates based on the CSP of P. vivax. We
demonstrate that these chimeric parasites are recognized by a
monoclonal antibody (MAb), 2F2, specific for the P. vivax VK210
CSP repeats (15) and that the in vivo infectivity of chimeric sporo-
zoites is strongly inhibited by this monoclonal antibody, as well as
by polyclonal antibodies raised against a recombinant P. vivax
CSP construct (16).
MATERIALS AND METHODS
Plasmid construction and parasite transfection. The transfection plas-
mid, pR-CSPv, carrying the repeat region of P. vivax, was derived from
plasmid pR-CSwt (17), which carries the CS gene of P. berghei (wild type
[WT]) and results from the combination of plasmids pIC-CSwt (18) and
pPv (Retrogen Inc., CA) encoding the VK210 repeat motif based on the
Salvador I (SalI) strain of P. vivax. Briefly, a PmlI-SexAI 567-bp fragment
was excised from pIC-CSwt and replaced with a PmlI-SexAI 675-bp frag-
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ment comprising the P. vivax VK210 CSP repeat region, which was codon
harmonized to optimize protein synthesis and folding in the P. berghei
transgenic host (19) and was excised from the engineered pPv. From the
resulting intermediate plasmid, pIC-CSPv, the entire CSP gene was ex-
cised as a KpnI-XhoI fragment and inserted into the transfection plasmid,
pR-CSPv. KpnI and SacI were used to linearize pR-CSPv prior to trans-
fection; WT P. berghei (strain ANKA) parasites were transfected as previ-
ously described (20).
Chimeric parasites were selected in Swiss Webster mice (NCI, Freder-
ick, MD) by treatment with pyrimethamine in drinking water (0.07 mg/
ml). Parasites surviving drug treatment were then cloned by means of a
limiting-dilution assay (21). Recombination at the 5= and 3= ends of the
locus was verified by PCR. The primers used to verify integration at the 5=
end of the construct are 5=F (TCACCCTCAAGTTGGGTAAAA) and 5=R
(CCTGTCCCCTGGTTGCTTA); the primers to verify integration at the
3= end are 3=F (TGTAAAAATGTGTATGTTGTGTGC) and 3=R (GTGC
CCATTACGACTTTGCT). To verify that the isolated clone did not have
contaminating WT P. berghei parasites, a PCR product flanking the SexAI
restriction site was digested with SexAI. The primers used for this PCR are
PbCS-F (AAGAAAGCAGAAGATTTGACCTT) and PbCS-R (AAGGTC
AAATCTTCTGCTTTCTT). Finally, DNA isolated from the cloned trans-
genic parasites was sequenced (Macrogen Inc., USA) to confirm the re-
placement of the P. berghei repeat region with the P. vivax repeat region
for the generation of P. berghei-P. vivax chimeric parasites.
Mosquito infection and parasite development. Anopheles stephensi
mosquitoes were fed on Swiss Webster mice (NCI, Frederick, MD) in-
fected with blood stages of cloned P. berghei-P. vivax CSRepeat (P. ber-
ghei-P. vivax) parasites. Development of viable male gametocytes in blood
was qualitatively assessed by means of an exflagellation assay. Briefly, 1.5
l of blood from a mouse with patent blood parasitemia was incubated at
room temperature for 20 min with 1.5 l of heparin (40 U/ml in 1
phosphate-buffered saline [PBS]) and 7 l of complete ookinete medium
(RPMI 1640 medium with 10% fetal calf serum, 25 mM HEPES, 2 mM
glutamine, 0.2 mM hypoxanthine, 12 mM sodium bicarbonate, 1 M
xanthurenic acid). After incubation, the mixture was placed on a slide and
observed under a light microscope (100 magnification).
Development of oocysts in mosquito midguts was assessed 14 days
post-blood meal. The midguts were dissected in sterile PBS and stained in
a 0.1% mercury chromate solution.
Infectivity of P. berghei-P. vivax sporozoites. The in vivo infectivity
of chimeric P. berghei-P. vivax sporozoites was assessed in 5- to 8-week-
old C57BL/6 mice both by assessing the liver parasite load, measured by
quantitative PCR (qPCR) (22), in mice that were challenged intrave-
nously (i.v.) with 1  104 P. berghei-P. vivax sporozoites and by the de-
velopment of blood-stage parasites after feeding with 3 P. berghei-P. vivax-
infected A. stephensi mosquitoes for 3 min.
Antibodies. Development of 3D11, a monoclonal antibody directed
against the repeat region of CSP of P. berghei (23), and 2F2, a monoclonal
antibody directed against the repeat region of P. vivax CSP (24), has been
previously described.
Polyclonal antibodies against P. vivax CSP were generated by immu-
nizing New Zealand White rabbits with 25 g VMP001 (16) in complete
Freund’s adjuvant, followed by 2 booster immunizations with 25 g
VMP001 in incomplete Freund’s adjuvant. Serum obtained post-3rd im-
munization was pooled and used in the present study.
IFA. An indirect immunofluorescence assay (IFA) was used to char-
acterize P. berghei-P. vivax sporozoties using monoclonal antibodies.
Briefly, 10 l of a sporozoite suspension (4  105 to 6  105 sporozoites/
ml) was air dried on poly-L-lysine-covered slides (Tekdon Inc., Myakka
City, FL) and incubated for 30 min at room temperature with 1 g/ml of
3D11 or 2F2 monoclonal antibody against the P. berghei (23) or the P.
vivax (15, 24, 25) CSP repeat region, respectively. The slides were then
washed with PBS-1% bovine serum albumin (BSA) and incubated for 30
min at room temperature with a secondary-antibody solution [Alexa
Fluor 488 F(ab=)2 fragment of goat anti-mouse IgG(HL); 2 mg/ml; In-
vitrogen]. Green-fluorescent sporozoites were visualized under an up-
right fluorescence microscope (Nikon Eclipse 90i).
Inhibition of sporozoite infectivity by passive transfer of monoclo-
nal antibodies or polyclonal rabbit sera directed against P. vivax CSP.
Three hundred micrograms of 2F2 antibody specific for the repeat region
of P. vivax (15) or 0.5 ml pooled sera from rabbits immunized with
VMP001, a recombinant P. vivax CSP (16), were passively transferred into
5- to 8-week-old C57BL/6 mice i.v. immediately prior to sporozoite chal-
lenge. Following antibody transfer, the mice were challenged with 1  104
sporozoites delivered by tail vein injection into each mouse. Forty-two
hours after challenge, livers were harvested to assess the parasite burden
by qPCR. In some experiments, mice receiving monoclonal antibody were
challenged by mosquito bites. For this purpose, 5- to 8-week-old C57BL/6
mice were anesthetized by intraperitoneal injection of 250 l of 2% aver-
tin, and then 400 g of 2F2 antibody was passively transferred i.v. prior to
feeding P. berghei-P. vivax-infected A. stephensi mosquitoes. For increased
stringency, we allowed 4 mosquitoes to feed for 5 min and then visually
examined them for a blood feed. The presence of sporozoites was then
assessed in those mosquitoes that fed to ensure that mice were exposed to
the bite of at least 1 infected mosquito.
Data analysis. Most of the data were plotted using Prism 4 software
(GraphPad). Unless otherwise stated, data were compared for significance
using a Mann-Whitney test.
RESULTS
Generation and biological characterization of P. berghei-P.
vivax chimeric parasites. Using a plasmid containing the se-
quences of the P. berghei CSP gene and a modified version of the
dihydrofolate reductase (DHFR) gene, which confers resistance to
pyrimethamine on transfected parasites, we generated P. ber-
ghei-P. vivax chimeric parasites. Briefly, we replaced the repeat
region of P. berghei CSP with the repeat domain of P. vivax CSP.
The P. vivax replacement represents the VK210 CSP sequence of
the P. vivax SalI strain, from nucleotides 268 to 825 (amino acids
90 to 275). P. berghei ANKA blood stages were transfected in vitro
with a plasmid linearized using KpnI and XhoI restriction en-
zymes, as described previously (21) (Fig. 1A). The transfected par-
asites were injected intravenously into Swiss Webster mice, and
transgenic parasites were selected under pyrimethamine treat-
ment. Ten days later, drug-resistant parasites were recovered and
cloned by limiting dilution.
PCR analysis was used to confirm recombination at the 5= and
3= ends for gene replacement (Fig. 1B), and the cloned parasites
were verified by PCR-restriction fragment length polymorphism
(RFLP) (Fig. 1C). The cloned parasites were sequenced to further
confirm that the P. berghei-P. vivax parasites have the correct in-
sertion in the CSP gene (Fig. 1D).
Mosquito infection. A cloned P. berghei-P. vivax parasite iso-
late was used to infect mice, which were then used to feed A.
stephensi mosquitoes. Transgenic parasites were evaluated by us-
ing standard methods, such as exflagellation and oocyst and
sporozoite counts, to compare them to the wild-type P. berghei.
Exflagellation of male P. berghei-P. vivax gametocytes, as-
sessed prior to feeding female A. stephensi mosquitoes on in-
fected mice, was normal and comparable to that of WT P. ber-
ghei ANKA parasites (data not shown). Twelve to 14 days after
mosquito feeding, P. berghei-P. vivax-infected mosquito mid-
guts had approximately 100 to 150 healthy-looking oocysts per
midgut, which was also comparable to WT P. berghei ANKA
parasites. Finally, on day 21, mosquito salivary glands were
dissected, and the parasite load was found to be comparable to
that of WT P. berghei ANKA (Table 1).
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Characterization of P. berghei-P. vivax sporozoites with
monoclonal antibodies. Sporozoites obtained from salivary
glands of P. berghei-P. vivax-infected mosquitoes were used for
IFA with antibodies specific for the repeat domain of P. vivax
(2F2) CSP. An antibody specific for the repeat region of P. berghei
(3D11) served as a control. The IFA results clearly demonstrated
that the chimeric P. berghei-P. vivax sporozoites were all uni-
formly positive for the anti-P vivax repeat antibodies and negative
for the antibody against P. berghei repeats (Fig. 2).
Infectivity of P. berghei-P. vivax chimeric parasites in mice.
To evaluate the in vivo fitness of the transgenic parasites, we chal-
lenged C57BL/6 mice with 1  104 sporozoites, delivered by i.v.
injection, from either WT P. berghei ANKA or P. berghei-P. vivax
parasites. Forty-two hours after infection, the parasite load in the
liver was measured by qPCR specific for the P. berghei 18S rRNA.
TABLE 1 Developmental characteristics and infectivity of P. berghei-P.
vivax parasites in A. stephensi mosquitoesa
Parasite
% of
midgut
infected
No. of
oocysts/
midgut
% of
salivary
gland
infected
No. of
sporozoites/
salivary
gland (103)
% of mice
infected
after
mosquito
bitesb
P. berghei-
P. vivax
80.72 54.76 75 8.5 100
P. berghei
ANKA
75.14 42.25 66 10 100
a Mean of 3 experiments, with at least 20 mosquitoes examined in each experiment.
b Three infected mosquitoes were allowed to feed on C57BL/6 mice for 3 min. Blood-
stage parasitemia was assessed 5 days later.
FIG 1 Generation of P. berghei-P. vivax (Pb-Pv) chimeric parasites. (A) Schematic representation of the approach used for replacing the CSP gene of P. berghei
ANKA with the P. vivax SalI repeat region. The locations of the primers used to verify recombination by PCR are indicated at the bottom. The restriction sites
shown are KpnI (K), PmlI (P), SexAI (Se), XhoI (Xh), and SacI (S). (B) Integration at the 5= and 3= ends of the replacement fragment was verified by PCR using
genomic DNA from P. berghei-P. vivax parasites. Primers 5=F and Pb-Pv R yield a 1,020-bp product; primers 3=F and 3=R yield a 1,000-bp product. (C) To
demonstrate that the parasite population was clonal, a 908-bp PCR fragment was amplified from the CSP gene using primers PbCS-F and PbCS-R. The PCR
product was then digested with SexAI, which does not cut the WT CSP gene. Genomic DNA from P. berghei ANKA was used as a control. (D) Comparison of CSP
amino acid sequences of P. berghei ANKA, P. berghei-P. vivax, and P. vivax strain Salvador I; the P. berghei-P. vivax amino acid sequence was derived from DNA
sequencing of clonal transgenic parasites. (E) In vivo infectivity of P. berghei-P. vivax sporozoites compared to WT P. berghei ANKA sporozoites, both injected
intravenously. ns, not significant; horizontal bars, geometric means.
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The data indicated that the infectivities of WT P. berghei ANKA
and P. berghei-P. vivax sporozoites were comparable, and there
was no statistically significant difference between the parasites.
The infectivity of the transgenic parasites was further confirmed
by delivering the parasites via the natural route, i.e., using mosquito
bites. Mice exposed to the bites of 3 infected mosquitoes demon-
strated patent blood-stage infection by day 5 postchallenge.
Anti-P. vivax antibodies inhibit the development of parasite
liver stages. In order to evaluate the utility of the transgenic par-
asites as a tool to assess the efficacy of future vaccines, we tested the
neutralization capabilities of anti-P. vivax antibodies in vivo. The
anti-repeat monoclonal antibody 2F2 was passively transferred
into mice immediately prior to an intravenous challenge with 1 
104 chimeric P. berghei-P. vivax sporozoites. As seen in Fig. 3, mice
that received 2F2 antibody showed a significant reduction in par-
asite load in the liver (99% reduction compared to naive controls).
In contrast, the group that received the irrelevant antibody had a
parasite load comparable to that of naive controls, confirming the
specificity of the results observed with the anti-P. vivax MAb 2F2.
To determine the effects of polyclonal antibodies that contain a
mixture of specificities (as opposed to the repeat-specific mono-
clonal antibody 2F2), we evaluated the neutralization capability of
rabbit polycolonal serum that was generated against a recombi-
nant P. vivax CSP protein, VMP001. Rabbit anti-VMP001 anti-
bodies recognized CSP on the surfaces of P. vivax sporozoites and
reacted to the whole protein (VMP001), in addition to the N-ter-
minal and C-terminal proteins, as well as a synthetic type 1 pep-
tide. As shown in Fig. 3B, similar to MAb 2F2, polyclonal rabbit
sera also reduced the liver parasite burden in comparison to mice
that either were naive or received preimmune rabbit serum. When
mice receiving 400 g of monoclonal antibody 2F2 were exposed
to the bites of 4 P. berghei-P. vivax-infected mosquitoes for 5 min,
we did not observe sterile protection. However, control mice (n 
5) receiving an irrelevant monoclonal antibody developed para-
sitemia at day 4, while mice receiving anti-parasite monoclonal
antibody (n  5) became patent at day 5. Taken together, these
results demonstrate that P. berghei-P. vivax sporozoites are highly
infectious and a stringent model to evaluate immune responses
FIG 2 Characterization of P. berghei-P. vivax sporozoites using anti-repeat
monoclonal antibodies. Monoclonal antibody 2F2, targeting the repeat region
of P. vivax CSP VK210, specifically recognizes P. berghei-P. vivax chimeric
sporozoites and P. vivax SalI sporozoites. No cross-reactivity was observed
against WT P. berghei ANKA sporozoites. Monoclonal antibody 3D11, specific
for the repeat region of P. berghei, reacts to wild-type P. berghei, but not to P.
vivax or P. berghei-P. vivax chimeric sporozoites.
FIG 3 Protection against P. berghei-P. vivax sporozoite challenge by passive transfer of monoclonal antibodies or hyperimmune sera. Following passive transfer
of monoclonal antibodies or sera, mice were challenged intravenously with 1  104 P. berghei-P. vivax sporozoites. Forty hours after challenge, livers were
harvested to determine parasite burdens by qPCR. Passive transfer of monoclonal antibody 2F2 (A) or rabbit polyclonal sera (B) had a significant protective effect
against P. berghei-P. vivax sporozoites compared to mice that received irrelevant antibody (ab.) or preimmune sera or to naive controls. The horizontal bars show
the geometrical means. *, P  0.05; **, P  0.01. The percent parasite burden inhibition in the liver is shown in parentheses. The results are representative of at
least two independent experiments. Each group consisted of 4 or 5 mice.
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that inhibit parasite development in the liver, as well as the acqui-
sition of sterile immunity after immunization with vaccine candi-
dates.
DISCUSSION
Studies on assessing protective immune responses against malaria
in general, and P. vivax in particular, are difficult due to the in-
ability to culture the parasite and to the lack of a suitable animal
model. Human studies are expensive, and therefore, this is not a
practical first step to evaluate vaccine candidates. Over the last
decade or so, transfection of Plasmodium has revolutionized the
ways in which protective immune responses can be evaluated us-
ing transgenic rodent parasites that have been transfected with the
gene encoding a specific human malaria antigen (14, 26–29). Ac-
tive- and passive-immunization studies directed toward these an-
tigens are more indicative of a biologically relevant immune re-
sponse than the evaluation of immunogenicity alone. Transgenic
parasites carrying the CSP, MSP, and P25 genes of P. falciparum
have been developed and are being used to evaluate vaccine can-
didates and/or platforms (14, 26–29). To date, only one transgenic
P. berghei sporozoite expressing P25 from P. vivax has been devel-
oped as a tool for evaluating the efficacy of vaccine candidates
(29).
Here, we describe the successful development, characteriza-
tion, and applicability of chimeric P. berghei parasites expressing
the repeat region of P. vivax CSP. We successfully replaced the P.
berghei repeat region with the VK210 repeat region of P. vivax. The
resulting parasites produce viable gametocytes and successfully
infect A. stephensi mosquitoes, in which their development is
comparable to that of WT P. berghei. The in vivo infectivity of P.
berghei-P. vivax sporozoites is comparable to that of WT P. berghei
in C57BL/6 mice. Moreover, feeding of P. berghei-P. vivax-in-
fected mosquitoes on naive C57BL/6 mice results in the develop-
ment of patent blood-stage parasitemia. Following immuniza-
tion, the true potential of a vaccine needs to be evaluated using a
natural route of sporozoite inoculation, which allows the partici-
pation of all components of the immune response in protection.
We used the transgenic parasites to evaluate their applicability
as a tool for assessing the efficacies of antibodies in protection.
Passive transfer of monoclonal antibodies or hyperimmune sera
into naive recipients conferred significant protection against P.
berghei-P. vivax sporozoite challenge. Mice that received 2F2 an-
tibody or hyperimmune rabbit sera both showed above 95% inhi-
bition of the parasite burden in the liver compared to the naive
controls, thus proving that the transgenic parasites can serve as an
important tool in evaluating protective anti-repeat immune re-
sponse. Given that sporozoites rapidly migrate through the circu-
latory system (30), the availability and affinity of circulating anti-
sporozoite antibodies determine their protective capacity. While
the monoclonal antibody 2F2 was able to decrease liver infection
by 90% of the sporozoites—as shown by measurement of the par-
asite load in the liver—and delayed the prepatent period by 1 day,
it does not appear to be efficient enough to confer sterile immu-
nity. Further comparative studies will be necessary to define the
dosage, avidity, and fine specificity of different monoclonal and
polyclonal antibodies capable of conferring sterile immunity. The
possibility that sterile immunity was not achieved due to genera-
tion of mutants or revertant parasites is unlikely; however, this is
an issue worth considering for future studies. Taken together,
these results demonstrate that the P. berghei-P. vivax parasites are
robust and that a natural mosquito bite challenge can be used as a
stringent test to assess the full potential of vaccine candidates.
Passive-transfer experiments in mice using serum samples from
volunteers immunized with novel vaccine candidates could po-
tentially be used to assess humoral protective capacity against P.
berghei-P. vivax sporozoites. Such studies should also be useful for
determining more accurate correlates between antibody titers and
protective efficacy against P. vivax infection.
Chimeric rodent malaria parasites are a simple, robust, and
practical tool for the in vivo evaluation of vaccine candidates
against malaria. This is the first report of the development of a
rodent parasite that can be used to evaluate the efficacy of the
circumsporozoite protein central repeat region of P. vivax. As the
replacement of the entire CSP gene could result in parasites with
reduced infectivity in both mice and mosquitoes (31), we chose to
first develop chimeric parasites in which we replaced only the P.
berghei CSP repeat domain with that of P. vivax, which is a well-
defined target of protective antibody responses. The successful
generation of parasites that are able to reproducibly infect mice
opens up the road to develop additional transgenic parasites ex-
pressing the N-terminal and C-terminal regions and, if possible,
the full-length CSP to evaluate T-cell-mediated immune-protec-
tive mechanisms.
Such parasites will help select future vaccine candidates for
clinical development. Over the last decade, the utility of chimeric
rodent parasites has been highlighted by an increasing number of
studies that report their use for the assessment of novel protein
constructs, recombinant viral vectors, and synthetic adjuvant for-
mulations (32–37). The P. berghei-P. vivax parasites we have gen-
erated should also facilitate the appraisal of new vaccine candi-
dates and represent a practical platform for evaluating CSP-based
protective immune responses against P. vivax.
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